Respiratory failure & ventilation
Early sevoflurane sedation in severe COVID-19-related lung injury patients. A pilot randomized controlled trial
An erratum to this article was published (Ann Intensive Care, 16 Jun 2024 ↗)
Authors' conclusion
No evident benefits were observed with short sevoflurane sedation on mortality and POD.
Study context
- Population
- Patients requiring mechanical ventilation due to severe COVID-19-related lung injury, four tertiary hospitals in Switzerland, April 2020–May 2021
- Participants
- 60 patients
- Comparison
- 48-hour sevoflurane sedation vs continuous intravenous sedation
- Sevofluranen = 28
- Controln = 32reference
- Primary endpoint
- Composite of:
- Mortality
- Persistent organ dysfunction (need for mechanical ventilation, vasopressors, or RRT)
- Follow-up
- Day 28
Methodological detailspilot, multicentre
- Pilot
- Multicentre
Primary result
As reported in the abstract
P = 0.916
Secondary outcomes
Mortality · 28 days
P = 0.817
Need for vasopressors · day 28 · significant difference
P = 0.028
Persistent organ dysfunction (POD) among 28-day survivors
- POD in 28-day survivors, sevoflurane vs control: 6 (26%) vs 8 (30%)
- P = 0.781
ICU and hospital LOS · 28 days
- Comparable between groups
Blood IL-6 levels · first few days after onset of lung injury
- Less distinctly elevated than expected
Safety
AKI · within 28 days
P = 0.001
Other registered adverse events · within 28 days
- Comparable between groups
Original publication
Early sevoflurane sedation in severe COVID-19-related lung injury patients. A pilot randomized controlled trial. Ann Intensive Care. Published 27 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →